[A18-66] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Last updated 22.03.2019
Project no.:
A18-66
Commission:
Commission awarded on 01.10.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant
Advantage in overall survival, but also disadvantages in side effects; hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.